Index trend and stocks in action October 24, 2019
Index trend and stocks in action October 24, 2019

Index trend and stocks in action October 24, 2019

Karan Dsij Article rating: 5.0

The level of 11,550 is immediate support for the Nifty and a sustainable move below this can create opportunities for further corrections towards 11,450 level. Meanwhile, the level of 11,700-11,715 poses stiff resistance for Nifty on the upside. Stocks in news: GMR Infrastructure, Yes Bank, HCL Technologies, PVR, Hindustan Aeronautics, DHFL.

U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets
U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets

U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets

Pritam Bhawar Article rating: 5.0

Lupin Limited received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depakote Extended-Release Tablets, 250 mg and 500 mg, of AbbVie Inc.

Larsen & Toubro awarded by a mega EPCC project
Larsen & Toubro awarded by a mega EPCC project

Larsen & Toubro awarded by a mega EPCC project

Pritam Bhawar Article rating: 4.0

Larsen and Toubro Hydrocarbon Engineering Limited (LTHE) on Wednesday, has been awarded a mega EPCC project by Hindustan Petroleum Corporation Limited (HPCL). LTHE is a wholly owned subsidiary of Larsen and Toubro.

Market ends in green after a volatile session
Market ends in green after a volatile session

Market ends in green after a volatile session

Nidhi Jani Article rating: 5.0

The BSE Sensex ended at 39058.83, up by 94.99 points or 0.24%. The broader indices ended mixed; the BSE Mid cap index fell 0.18%, while Small cap index was up by 0.24%.

Jubilant Life Sciences gains 4 per cent at closing hours
Jubilant Life Sciences gains 4 per cent at closing hours

Jubilant Life Sciences gains 4 per cent at closing hours

Shohini Nath Article rating: 5.0

Jubilant Life Sciences’ material wholly owned subsidiary Jubilant Pharma through one of its wholly owned subsidiaries has received Abbreviated New Drug Application (ANDA) final approval

 


The catch behind No-Cost EMIs
The catch behind No-Cost EMIs

The catch behind No-Cost EMIs

Henil Shah Article rating: 5.0

EMI is something some people think of casually, while some consider it as a ticking bomb. However, what if you only need to pay the principal amount in installments? Read on to find out more on whether to opt for no cost EMIs or not.

Syngene reported 64 per cent PAT growth in Q2FY20
Syngene reported 64 per cent PAT growth in Q2FY20

Syngene reported 64 per cent PAT growth in Q2FY20

Amir Shaikh Article rating: 3.5

In the second quarter of FY20, Syngene reported 11 per cent growth in the  total income to Rs. 485.2 crore from Rs. 436.8 crore in corresponding quarter a year ago

RSS
First24902491249224932495249724982499Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR